3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Breast
1
Conditions
Breast Neoplasms
36
Neoplasms
7
Neoplasm Metastasis
7
Endometrial Neoplasms
7
Ovarian Neoplasms
5
Triple Negative Breast Neoplasms
4
Breast Diseases
3
Brain Neoplasms
3
Sarcoma
2
Neoplasms by Site
2
Meningioma
2
Glioblastoma
2
Fallopian Tube Neoplasms
2
Breast Neoplasms, Male
2
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumor, Adult
1
Sarcoma, Kaposi
1
Retinoblastoma
1
Recurrent Ovarian High Grade Serous Adenocarcinoma
1
Recurrence
1
Prostatic Neoplasms
1
Pathologic Complete Response
1
Osteosarcoma
1
Neurofibromatosis 1
1
Neoplasm, Residual
1
Multiple Myeloma
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lung Neoplasms
1
Interventions
Carboplatin
4
pertuzumab
2
durvalumab
2
Tretinoin
2
Trastuzumab
2
Standard of Care
2
Paclitaxel
2
Oxaliplatin
2
zanidatamab
1
veliparib
1
tucatinib
1
trilaciclib
1
trebananib
1
trastuzumab duocarmazine
1
toripalimab
1
tislelizumab
1
talazoparib
1
sarilumab
1
relugolix
1
regorafenib
1
pexidartinib
1
pembrolizumab
1
patritumab
1
olaparib
1
niraparib
1
nimotuzumab
1
neratinib
1
ganitumab
1
enzalutamide
1
dostarlimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Pathologic Complete Response
×
abemaciclib
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled